Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1992 6
1993 4
1994 4
1995 1
1996 2
1997 8
1998 3
1999 2
2000 1
2001 6
2002 8
2003 14
2004 6
2005 12
2006 15
2007 10
2008 13
2009 15
2010 12
2011 20
2012 19
2013 26
2014 20
2015 12
2016 10
2017 9
2018 5
2019 2
2020 4
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Flather MD, et al. Eur Heart J. 2005 Feb;26(3):215-25. doi: 10.1093/eurheartj/ehi115. Epub 2005 Jan 9. Eur Heart J. 2005. PMID: 15642700 Clinical Trial.
The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection fraction. ...There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcom …
The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients >/=70 years, regardless of ejection …
Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
Cannata F, Stefanini G, Carlo-Stella C, Chiarito M, Figliozzi S, Novelli L, Lisi C, Bombace S, Panico C, Cosco F, Corrado F, Masci G, Mazza R, Ricci F, Monti L, Ferrante G, Santoro A, Francone M, da Costa BR, Jüni P, Condorelli G. Cannata F, et al. J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491. J Cardiovasc Med (Hagerstown). 2023. PMID: 37285278 Clinical Trial.
This study aims to evaluate the cardioprotective effects of the beta blocker nebivolol in a prospective, placebo-controlled, superiority randomized trial in patients with breast cancer or diffuse large B cell lymphoma (DLBCL) who have a normal cardiac function and will rec …
This study aims to evaluate the cardioprotective effects of the beta blocker nebivolol in a prospective, placebo-controlled, superior …
Managing endothelial dysfunction in COVID-19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double-blind, placebo-controlled, randomized clinical trial.
Matli K, Al Kotob A, Jamaleddine W, Al Osta S, Salameh P, Tabbikha R, Chamoun N, Moussawi A, Saad JM, Atwi G, Saad TA, Jamal O, Mokhbat J, Ghanem G. Matli K, et al. Clin Transl Sci. 2022 Oct;15(10):2323-2330. doi: 10.1111/cts.13369. Epub 2022 Jul 20. Clin Transl Sci. 2022. PMID: 35808843 Free PMC article. Clinical Trial.
In this pilot, double-blind, placebo-controlled, randomized clinical trial, we assigned patients who were admitted to the hospital with mild, moderate, or severe COVID-19 infection to receive, on top of optimal medical therapy, either an endothelial protocol consisting of (Nicora …
In this pilot, double-blind, placebo-controlled, randomized clinical trial, we assigned patients who were admitted to the hospital with mild …
Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial.
Gungor G, Perk H, Soyupek S, Baykal B, Demir M, Sezer MT. Gungor G, et al. Eur J Intern Med. 2022 Sep;103:69-75. doi: 10.1016/j.ejim.2022.06.013. Epub 2022 Jun 23. Eur J Intern Med. 2022. PMID: 35752527 Clinical Trial.
This study investigated the effect of Nebivolol and Metoprolol on erectile functions in hypertensive men. ...In the non-ED group, both drugs decreased the IIEF-5 score, but the decrease for Metoprolol (p = 0.001) was more than that for Nebivolol (p = 0.012). Plasma …
This study investigated the effect of Nebivolol and Metoprolol on erectile functions in hypertensive men. ...In the non-ED group, bot …
Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial.
Shibata MC, Curl-Roper J, Van Veldhuisen DJ, Roughton M, Coats AJS, Flather M. Shibata MC, et al. Clin Res Cardiol. 2021 Aug;110(8):1193-1201. doi: 10.1007/s00392-020-01768-w. Epub 2020 Nov 2. Clin Res Cardiol. 2021. PMID: 33136223 Clinical Trial.
BACKGROUND: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the effect of nebivolol on 6MWT from the SENIORS trial. METHODS AND RESULTS: The SENIORS trial evaluated nebivolol versus placebo …
BACKGROUND: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the …
The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
Studinger P, Tabák ÁG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tislér A. Studinger P, et al. J Clin Hypertens (Greenwich). 2013 Dec;15(12):910-7. doi: 10.1111/jch.12210. Epub 2013 Oct 4. J Clin Hypertens (Greenwich). 2013. PMID: 24119182 Free PMC article. Clinical Trial.
AIx remained unchanged, while AIx@75 decreased significantly by 5.4%2.5% in the nebivolol group. According to general linear models, individual change in heart rate was a strong predictor of change in AIx in the carvedilol group (r(2) =0.23, P=.03) although no similar asso …
AIx remained unchanged, while AIx@75 decreased significantly by 5.4%2.5% in the nebivolol group. According to general linear models, …
Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia.
Rhee MY, Kim CH, Ahn Y, Shin JH, Han SH, Kang HJ, Hong SJ, Kim HY. Rhee MY, et al. Drug Des Devel Ther. 2020 Nov 17;14:5005-5017. doi: 10.2147/DDDT.S280055. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33235439 Free PMC article. Clinical Trial.
PURPOSE: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and hyperlipidemia. PATIENTS AND METHODS: Eligible patients, after more than 4 weeks of therapeutic lifestyle change, were randomly assigned to t …
PURPOSE: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and h …
Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary Artery Disease.
Hung OY, Molony D, Corban MT, Rasoul-Arzrumly E, Maynard C, Eshtehardi P, Dhawan S, Timmins LH, Piccinelli M, Ahn SG, Gogas BD, McDaniel MC, Quyyumi AA, Giddens DP, Samady H. Hung OY, et al. J Am Heart Assoc. 2016 Jan 25;5(1):e002764. doi: 10.1161/JAHA.115.002764. J Am Heart Assoc. 2016. PMID: 26811165 Free PMC article. Clinical Trial.
Nebivolol patients had decreased lumen and vessel areas along with increased plaque area, resulting in more constrictive remodeling (P=0.002). ...Importantly, after adjusting for beta-blocker, low-WSS segments remained significantly associated with lumen loss and plaque pr
Nebivolol patients had decreased lumen and vessel areas along with increased plaque area, resulting in more constrictive remodeling (
The Effects of Nebivolol and Irbesartan on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients with Intradialytic Hypertension.
Theodorakopoulou M, Loutradis C, Bikos A, Angeloudi E, Schoina M, Raptis V, Liakopoulos V, Papagianni A, Sarafidis P. Theodorakopoulou M, et al. Blood Purif. 2021;50(1):73-83. doi: 10.1159/000507913. Epub 2020 Oct 5. Blood Purif. 2021. PMID: 33017836 Clinical Trial.
Single-dose nebivolol also produced marginally lower 24-h c-SBP (p = 0.064) and lower 24-h central diastolic BP (c-DBP) (p = 0.029). Weekly administration of both drugs reduced postdialysis c-SBP (baseline: 144.1 15.3; nebivolol: 131.8 14.1, p = 0.014; irbesartan: 1 …
Single-dose nebivolol also produced marginally lower 24-h c-SBP (p = 0.064) and lower 24-h central diastolic BP (c-DBP) (p = 0.029). …
Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial.
Punzi H, Lewin A, Lukić T, Goodin T, Wei Chen. Punzi H, et al. Ther Adv Cardiovasc Dis. 2010 Dec;4(6):349-57. doi: 10.1177/1753944710387629. Ther Adv Cardiovasc Dis. 2010. PMID: 21088095 Free article. Clinical Trial.
RESULTS: Baseline SBP/DBP (mmHg) was similar in both treatment groups (nebivolol: 156/100; placebo: 157/101). A total of 135 (96%) and 121 (89%) nebivolol- and placebo-treated participants completed the double-blind phase, respectively. ...The safety and tolerabilit …
RESULTS: Baseline SBP/DBP (mmHg) was similar in both treatment groups (nebivolol: 156/100; placebo: 157/101). A total of 135 (96%) an …
246 results